TX-MAVENIR
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announced that it has pioneered a breakthrough Operations Co-Pilot that harnesses the power of generative AI (GenAI) to improve service-level agreements (SLAs) and optimize operational efficiency for communications service providers (CSPs). The innovation, which has been developed in collaboration with NVIDIA and Amazon Web Services (AWS), showcases the potential of GenAI to effectively define a Service Assurance AI/Ops Platform – reducing the burden on operations, support and maintenance teams and enhancing their ability to meet SLAs.
Mavenir’s Operations Co-Pilot for RAN Service Assurance (RSA) automates network troubleshooting, enabling mobile network operators to rapidly and accurately anticipate network issues and address detected network impairments before they become critical. The Operations Co-Pilot significantly reduces manual debugging effort, development and maintenance lead times to enhance IT operations, service availability and delivery for increasingly complex mobile networks.
Utilizing the power of GenAI with large language models (LLMs) trained on detailed key performance indicators (KPIs), counters, logs and traces from network infrastructure, Mavenir, together with NVIDIA and AWS, is creating a suite of Operations Co-Pilot solutions that will transform the operations management of telecom networks through intelligent automation. This new framework – built on NVIDIA Tensor Core GPUs and the NVIDIA AI Enterprise software platform for generative AI running on AWS – leverages Mavenir’s Open RAN architecture to provide accessibility into multiple open interfaces that can deliver the data needed to train and optimize domain-specific telecom LLMs.
Mavenir’s Chief Technology and Strategy Officer Bejoy Pankajakshan commented: “Our new Operations Co-Pilot framework has the potential to be a game-changer for operators, delivering a wealth of fault prediction and root cause analysis capabilities with AI-powered accuracy and speed. This industry-first solution is built on the transformative foundation of NVIDIA GPUs operating on AWS and enabled by Mavenir data, which can be accessed via numerous interfaces in the Open RAN and in the Packet Core for complete end-to-end visibility.”
He added: “The three key use cases of Core Dump Analysis, Log Similarity Search feature and Log Anomaly Detection can be used together to maximize the automated efficiency gains. Combining information from these trained LLMs will provide broader and deeper coverage of all fault and anomaly scenarios, enabling very early prediction of potential problems in the network. Moreover, as these solutions evolve, the models have the ability to continuously learn and optimize based on user feedback and iterative training with further logs, KPIs and traces, promising even greater gains.”
“In today’s fast-paced digital landscape, generative AI is a force multiplier for enterprises everywhere,” said Chris Penrose, global head of business development for telco at NVIDIA. “Mavenir’s framework, built on the NVIDIA AI Enterprise platform for streamlining the development and deployment of AI, will unlock a new level of operational efficiency for communications service providers.”
Notes to editors: Watch the video overview: Mavenir’s Operations Co-Pilot for RAN Service Assurance (RSA)
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610302138/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)16.2.2025 00:00:00 CET | Press release
OBODENCE™ and XBRYK™ approved by the European Commission (EC) for all indications referencing Prolia and Xgeva, respectivelyMarks Samsung Bioepis’ 10th and 11th product and first endocrinology treatment approved by the EC – adding to its growing portfolio of biosimilars Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars referencing Prolia and Xgeva – formerly referred to as SB16. OBODENCE, referencing Prolia, has been approved for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. XBRYK, referencing Xgeva, has been approved for the prevention of skel
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)15.2.2025 00:50:00 CET | Press release
In the MOTION Phase 3 study, ROMVIMZA met primary endpoint of improved objective response rate (ORR) compared to placebo and all key secondary endpoints with statistically significant and clinically meaningful improvements in quality-of-life measures, and demonstrated well-tolerated safety profile Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214768549/en/ “
Venture Global, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call14.2.2025 19:17:00 CET | Press release
Venture Global, Inc. (“Venture Global”)(NYSE: VG) announced today that it plans to issue its earnings release with respect to fourth quarter and full year 2024 financial results before market open on Thursday, March 6, 2025. Venture Global will host a conference call for investors and analysts beginning at 9:00 am Eastern Time (ET) on March 6, 2025, to discuss fourth quarter and full year results and provide guidance for the 2025 fiscal year. A listen-only webcast of the call and accompanying slide presentation will be available at Venture Global’s Investor Relations website HERE. After the conclusion of the webcast, a replay will be made available on the Venture Global website. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s fir
Asa Gudmundsdottir Wright Award Presented as Plans for New Icelandic Academy of Science & Innovation Announced14.2.2025 17:35:00 CET | Press release
Recognizing Contributions to Science and Innovation Iceland’s President, Halla Tomasdottir, presented the Asa Gudmundsdottir Wright Award at a ceremony at the presidential residence. This year’s recipients are G. Fertram Sigurjonsson, Founder and CEO of Kerecis, and Jon Atli Benediktsson, Rector of the University of Iceland. The award honors individuals who have made significant contributions to science and innovation in Iceland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214199674/en/ President Halla Tomasdottir and Kerecis Founder and CEO Fertram Sigurjonsson (Photo: Business Wire) During the ceremony, plans were also announced for the establishment of the Icelandic Academy of Science & Innovation, into which the award recipients will be inducted as members. The academy will provide a platform for collaboration between researchers, entrepreneurs, industry representatives, and academia. It will uphold the tradition o
Riskified To Report Fourth Quarter and Full-Year 2024 Financial Results on Wednesday, March 514.2.2025 17:33:00 CET | Press release
Riskified Ltd. (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced it will release its fourth quarter and full-year 2024 financial results before the market opens on March 5, 2025. On that day management will host a conference call and webcast at 8:30 a.m. ET to discuss the company's business and financial results. Riskified Fourth Quarter and Full-Year 2024 Financial Results Conference Call When: Wednesday, March 5, 2025 Time: 8:30 a.m. ET Dial-in: To access the conference call via telephone, please register via this registration link and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. Webcast: A live and archived webcast of the conference call will be accessible from the “Events & Presentations” section of the Company’s Investor Relations website at https://ir.riskified.com/. About Riskified Riskified (NYSE:RSKD) empowers businesses to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom